Circulating MrgD in Pulmonary Hypertension

Circulating MrgD Change in Patients With Pulmonary Hypertension

The aim of the study is to observe the change of the circulating MrgD level in patients with pulmonary hypertension compared with subjects without pulmonary hypertension.

Study Overview

• Status: Recruiting
• Conditions: Pulmonary Hypertension
• Intervention / Treatment: Diagnostic test: Western blot

• Study Type: Observational
• Enrollment (Estimated): 90

Contacts and Locations

• Study Contact: Name: Panpan Hao, MD; Phone Number: 8618560086593; Email: panda.how@sdu.edu.cn

Study Locations

• China
  • Shandong
    • Jinan, Shandong, China, 250012
      • Recruiting
      • Qilu Hospital of Shandong University
      • Contact: Panpan Hao, MD, PHD; Email: panda.how@126.com
      • Sub-Investigator: Hongyu Zhong, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

Patients with pulmonary hypertension and control subjects

Description

Inclusion criteria for patients with pulmonary hypertension：

1. Male or female aged ≥18 years
2. Right heart catheterisation to check the mean pulmonary artery pressure (mPAP) ≥25mmHg
3. The patient is willing and able to provide written informed consent.

Exclusion criteria for patients with pulmonary hypertension：

1. Age less than 18 years old
2. Mean pulmonary artery pressure (mPAP) <25mmHg
3. Unable to provide informed written consent for participation in the study
4. Renal insufficiency
5. Liver insufficiency
6. Malignant tumor
7. Active infection
8. Pregnancy

Inclusion criteria for control subjects：

1. Male or female aged ≥18 years
2. No evidence of pulmonary hypertension on echocardiography or mean pulmonary artery pressure (mPAP) < 25 mmHg on right heart catheterization, and no evidence of clinically relevant heart disease
3. No evidence of clinically relevant pulmonary disease

Exclusion criteria for control subjects：

1. Age less than 18 years old
2. Mean pulmonary artery pressure (mPAP) ≥25mmHg
3. Unable to provide informed written consent for participation in the study
4. Symptoms of heart failure or clinically relevant lung disease
5. Renal insufficiency
6. Liver insufficiency
7. Malignant tumor
8. Active infection
9. Pregnancy

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
PAH	Diagnostic test: Western blot; Samples were measured by Western blot using a solution for the separation of lymphocytes from peripheral blood.
Non-PAH	Diagnostic test: Western blot; Samples were measured by Western blot using a solution for the separation of lymphocytes from peripheral blood.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Circulating MrgD level	From 2022 to 2024

Collaborators and Investigators

• Sponsor: Qilu Hospital of Shandong University

Study record dates

Study Major Dates

• Study Start (Actual): April 10, 2024
• Primary Completion (Estimated): May 10, 2024
• Study Completion (Estimated): June 1, 2024

Study Registration Dates

• First Submitted: April 10, 2024
• First Submitted That Met QC Criteria: April 10, 2024
• First Posted (Estimated): April 15, 2024

Study Record Updates

• Last Update Posted (Estimated): April 15, 2024
• Last Update Submitted That Met QC Criteria: April 10, 2024
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Respiratory Tract Diseases; Lung Diseases; Hypertension; Hypertension, Pulmonary
• Other Study ID Numbers: MrgD and PAH

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No